- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03822728
Intra-parotid Facial Nerve Imaging in Parotidectomy
Postoperative Facial Weakness in Parotidectomy for Deep Seated Parotid Tumor With or Without Intra-parotid Facial Nerve Imaging (3D Double-Echo Steady-State With Water Excitation MRI Imaging)
In this study, the investigators will evaluate the clinical usefulness of 3 dimensional double echo steady state MRI (3D-DESS MRI) for functional preservation of the facial nerve during parotidectomy. Preoperative 3D-DESS MRI imaging can provide information about the anatomical relationship between the tumor and the facial nerve in the parotid gland.
Because the risk of postoperative facial weakness is relatively high in the deep-seated parotid tumors, the investigators will exclude the patients with the superficial parotid tumors (determined by preoperative CT or US) and only include the patients with deep seated parotid tumors in this trial.
The main outcome of our study is the incidence of immediate postoperative facial weakness, and the secondary outcome is the incidence of facial weakness at postoperative 6 months.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Surgical removal of tumors arising from the parotid gland (benign or malignant) is treatment of choice. However, the most detrimental complication of parotidectomy is facial weakness or facial nerve palsy, because the facial nerve crosses in the mid-portion of the parotid gland.
Numerous studies indicated the incidence of temporary facial weakness as 5-45% and permanent facial palsy as 0-15% after parotidectomy. To reduce this complication, the investigators will apply the modern technique of MRI imaging to inform the anatomical relationship between the tumor and the facial nerve within the parotid gland preoperatively. Three dimensional double echo steady state MRI imaging (3D-DESS MRI) has been reported useful for the intra-parotid facial nerve imaging.
Thus, the investigators will evaluate the clinical usefulness of 3D-DESS MRI for functional preservation of the facial nerve during parotidectomy. Preoperative 3D-DESS MRI imaging can provide information about the anatomical relationship between the tumor and the facial nerve in the parotid gland.
In the retrospective series, the investigators found that there were 25.6% temporary facial weakness and 10.3% permanent (> 6 months) facial weakness after parotidectomy for deep-seated parotid tumors (plus tumors located in both deep and superficial parotid gland); whereas 6.7% and 3.6% facial weakness respectively for superficially located parotid tumors. Because the risk of postoperative facial weakness is relatively high in the deep-seated parotid tumors, the investigators will exclude the patients with the superficial parotid tumors (determined by preoperative CT or US) and only include the patients with deep seated parotid tumors in this trial.
The main outcome of our study is the incidence of immediate postoperative facial weakness, and the secondary outcome is the incidence of facial weakness at postoperative 6 months.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Seoul, Korea, Republic of, 135-710
- Samsung Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Parotid tumors subject to the surgery (parotidectomy)
- Parotid deep lobe tumors or tumor located in both superficial and deep parotid glands (Tumor medial to the facial nerve line, a line connecting the lateral border of mandible and the posterior belly of digastric muscle on CT scans or tumors crossing the facial nerve line on CT scans)
- Benign or malignant tumors
- Any size of parotid tumors
Exclusion Criteria:
- Superficially located parotid tumor on CT or US (Tumor lateral to the facial nerve line, a line connecting the lateral border of mandible and the posterior belly of digastric muscle on CT scans)
- Previous parotid surgery in the affected parotid gland (Revision parotid surgery)
- Preoperative facial nerve palsy
- Cases with the facial nerve sacrifice during surgery for oncological purpose (malignancy)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
No Intervention: Without 3D-DESS MRI
As for deep seated tumors in preoperative CT or US (or tumors in both superficial and deep parotid glands), the patients will undergo surgery without 3D-DESS MRI (currently routine practice).
|
|
|
Experimental: With 3D-DESS MRI
As for deep seated tumors in preoperative CT or US (or tumors in both superficial and deep parotid glands), preoperative 3D-DESS MRI will be additionally performed to delineate the intra-parotid facial nerve.
|
3D-DESS MRI has been reported useful for the intra-parotid facial nerve imaging.
It can provide information about the anatomical relationship between the tumor and the facial nerve in the parotid gland.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Immediate postoperative facial weakness
Time Frame: Postoperative day 1
|
Evaluation of facial function using Facial palsy grading system, immediately after parotidectomy. Measures: House-Brackmann Facial Nerve Grading System (1: Normal, 2: Mild dysfunction, 3: Moderately dysfunction, 4: Moderately severe dysfunction, 5: Severe dysfunction, 6: Total paralysis) |
Postoperative day 1
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Permanent postoperative facial weakness
Time Frame: Postoperative 6 months
|
Evaluation of facial function using Facial palsy grading system, at 6 months after parotidectomy. Measures: House-Brackmann Facial Nerve Grading System (1: Normal, 2: Mild dysfunction, 3: Moderately dysfunction, 4: Moderately severe dysfunction, 5: Severe dysfunction, 6: Total paralysis) |
Postoperative 6 months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Han-Sin Jeong, MD, Samsung Medical Center
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2017-07-084
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Facial Nerve Paresis
-
University of UtahCompletedSynkinesis | Facial Asymmetry | Facial Nerve Injuries | Facial Paresis Associated With Facial Nerve Dysfunction
-
Assiut UniversityRecruiting
-
University of Missouri-ColumbiaCompleted
-
University Health Network, TorontoTerminated
-
Boston Children's HospitalHoward Hughes Medical InstituteRecruitingOcular Motility Disorders | Facial Palsy | Synkinesis | Sixth Nerve Palsy | Mobius Syndrome | Congenital Fibrosis of Extraocular Muscles | Duane Retraction Syndrome | Duane Radial Ray Syndrome | Brown Syndrome | Marcus Gunn Syndrome | Strabismus Congenital | Horizontal Gaze Palsy | Horizontal Gaze Palsy With Progressive... and other conditionsUnited States
-
University Hospital, CaenTerminatedFacial ParesisFrance
-
Assistance Publique - Hôpitaux de ParisRecruitingQuality of Life | Facial Palsy | Motor Recovery | Self-rehabilitationFrance
-
Assiut UniversityNot yet recruiting
-
Mayo ClinicCompletedFacial Paralysis | Parotid NeoplasmsUnited States
-
Kriya Therapeutics, Inc.RecruitingRP-008 in Combination With Daily Oral Varenicline for the Treatment of Trigeminal Neuralgia (RELIEF)Trigeminal NeuralgiaCanada
Clinical Trials on 3D-DESS MRI (3 dimensional double echo steady state MRI)
-
University Hospital, BordeauxCompletedHypertrophic Cardiomyopathy | Mechanical Hyper-synchronicityFrance
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RecruitingAcute Myeloid Leukemia | Acute Promyelocytic Leukemia With PML-RARAUnited States
-
SWOG Cancer Research NetworkNational Cancer Institute (NCI)Not yet recruitingStage II Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8 | Stage III Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8 | Soft Tissue Sarcoma of the Trunk and Extremities | Recurrent Soft Tissue Sarcoma of the Trunk and Extremities | Resectable Soft Tissue Sarcoma of the Trunk...
-
National Cancer Institute (NCI)CompletedAdult Giant Cell Glioblastoma | Adult Glioblastoma | Adult GliosarcomaUnited States
-
Children's Oncology GroupRecruitingGerminoma | Diabetes Insipidus | Pineal Region Germinoma | Suprasellar Germinoma | Basal Ganglia Germinoma | Thalamic GerminomaUnited States, Australia, Canada
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedStage I Kidney Wilms Tumor | Stage II Kidney Wilms Tumor | Stage III Kidney Wilms TumorUnited States, Canada, Australia, New Zealand, Puerto Rico, Israel, Switzerland
-
National Cancer Institute (NCI)NRG OncologyCompletedPancreatic Adenocarcinoma | Pancreatic Ductal Adenocarcinoma | Pancreatic Intraductal Papillary-Mucinous Neoplasm | Stage I Pancreatic Cancer AJCC v6 and v7 | Stage II Pancreatic Cancer AJCC v6 and v7United States, Canada, Israel, Belgium
-
ECOG-ACRIN Cancer Research GroupNational Cancer Institute (NCI)RecruitingBiochemically Recurrent Prostate Carcinoma | Metastatic Prostate Carcinoma | Prostate Adenocarcinoma | Stage IVB Prostate Cancer AJCC v8United States